Fig. 6From: Anti-vascular endothelial growth factor for neovascular age-related macular degeneration: a meta-analysis of randomized controlled trialsSerious systemic adverse events comparing bevacizumab with ranibizumab at 2 years. M-H, Mantel–Haenszel statisticsBack to article page